Annual long term liabilities:
$897.01M-$38.16M(-4.08%)Summary
- As of today (September 16, 2025), RARE annual total long term liabilities is $897.01 million, with the most recent change of -$38.16 million (-4.08%) on December 31, 2024.
- During the last 3 years, RARE annual long term liabilities has risen by +$478.54 million (+114.35%).
- RARE annual long term liabilities is now -4.08% below its all-time high of $935.16 million, reached on December 31, 2023.
Performance
RARE Long term liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly long term liabilities:
$47.46M+$275.00K(+0.58%)Summary
- As of today (September 16, 2025), RARE quarterly total long term liabilities is $47.46 million, with the most recent change of +$275.00 thousand (+0.58%) on June 30, 2025.
- Over the past year, RARE quarterly long term liabilities has increased by +$2.20 million (+4.86%).
- RARE quarterly long term liabilities is now -35.87% below its all-time high of $74.00 million, reached on December 31, 2020.
Performance
RARE quarterly long term liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Long term liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
RARE Long term liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -4.1% | +4.9% |
| 3 y3 years | +114.3% | +28.0% |
| 5 y5 years | +137.0% | +29.5% |
RARE Long term liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -4.1% | +114.3% | -1.6% | +28.0% |
| 5 y | 5-year | -4.1% | +137.0% | -35.9% | +42.5% |
| alltime | all time | -4.1% | >+9999.0% | -35.9% | >+9999.0% |
RARE Long term liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $47.46M(+0.6%) |
| Mar 2025 | - | $47.18M(+0.1%) |
| Dec 2024 | $897.01M(-4.1%) | $47.14M(+2.1%) |
| Sep 2024 | - | $46.19M(+2.1%) |
| Jun 2024 | - | $45.26M(+1.6%) |
| Mar 2024 | - | $44.54M(-7.6%) |
| Dec 2023 | $935.16M(+0.4%) | $48.22M(+15.1%) |
| Sep 2023 | - | $41.90M(-0.4%) |
| Jun 2023 | - | $42.06M(+2.8%) |
| Mar 2023 | - | $40.92M(-4.0%) |
| Dec 2022 | $931.74M(+122.7%) | $42.63M(+14.1%) |
| Sep 2022 | - | $37.36M(+0.8%) |
| Jun 2022 | - | $37.07M(+1.0%) |
| Mar 2022 | - | $36.70M(-17.9%) |
| Dec 2021 | $418.47M(+0.7%) | $44.72M(+32.4%) |
| Sep 2021 | - | $33.78M(+1.4%) |
| Jun 2021 | - | $33.31M(-15.0%) |
| Mar 2021 | - | $39.17M(-47.1%) |
| Dec 2020 | $415.57M(+9.8%) | $74.00M(+122.2%) |
| Sep 2020 | - | $33.31M(-9.1%) |
| Jun 2020 | - | $36.63M(-48.7%) |
| Mar 2020 | - | $71.34M(+74.1%) |
| Dec 2019 | $378.43M | $40.97M(+31.5%) |
| Sep 2019 | - | $31.17M(0.0%) |
| Jun 2019 | - | $31.17M(0.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2019 | - | $31.17M(-13.2%) |
| Dec 2018 | $35.92M(-1.0%) | $35.92M(+0.2%) |
| Sep 2018 | - | $35.87M(-0.4%) |
| Jun 2018 | - | $36.00M(-0.3%) |
| Mar 2018 | - | $36.11M(-0.5%) |
| Dec 2017 | $36.28M(+467.6%) | $36.28M(+594.1%) |
| Sep 2017 | - | $5.23M(-3.4%) |
| Jun 2017 | - | $5.41M(-3.1%) |
| Mar 2017 | - | $5.59M(-12.6%) |
| Dec 2016 | $6.39M(+1039.6%) | $6.39M(-27.7%) |
| Sep 2016 | - | $8.85M(+45.6%) |
| Jun 2016 | - | $6.07M(+35.6%) |
| Mar 2016 | - | $4.48M(+698.6%) |
| Dec 2015 | $561.00K(+11.1%) | $561.00K(-11.5%) |
| Sep 2015 | - | $634.00K(-7.3%) |
| Jun 2015 | - | $684.00K(+43.1%) |
| Mar 2015 | - | $478.00K(-5.3%) |
| Dec 2014 | $505.00K(-86.0%) | $505.00K(-5.3%) |
| Sep 2014 | - | $533.00K(-4.8%) |
| Jun 2014 | - | $560.00K(+207.7%) |
| Mar 2014 | - | $182.00K(-95.0%) |
| Dec 2013 | $3.62M(+359.3%) | $3.62M(+97.8%) |
| Sep 2013 | - | $1.83M(+61.1%) |
| Jun 2013 | - | $1.14M(+44.2%) |
| Dec 2012 | $788.00K(+61.8%) | $788.00K |
| Dec 2011 | $487.00K | - |
FAQ
- What is Ultragenyx Pharmaceutical Inc. annual total long term liabilities?
- What is the all time high annual long term liabilities for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. annual long term liabilities year-on-year change?
- What is Ultragenyx Pharmaceutical Inc. quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Ultragenyx Pharmaceutical Inc.?
- What is Ultragenyx Pharmaceutical Inc. quarterly long term liabilities year-on-year change?
What is Ultragenyx Pharmaceutical Inc. annual total long term liabilities?
The current annual long term liabilities of RARE is $897.01M
What is the all time high annual long term liabilities for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high annual total long term liabilities is $935.16M
What is Ultragenyx Pharmaceutical Inc. annual long term liabilities year-on-year change?
Over the past year, RARE annual total long term liabilities has changed by -$38.16M (-4.08%)
What is Ultragenyx Pharmaceutical Inc. quarterly total long term liabilities?
The current quarterly long term liabilities of RARE is $47.46M
What is the all time high quarterly long term liabilities for Ultragenyx Pharmaceutical Inc.?
Ultragenyx Pharmaceutical Inc. all-time high quarterly total long term liabilities is $74.00M
What is Ultragenyx Pharmaceutical Inc. quarterly long term liabilities year-on-year change?
Over the past year, RARE quarterly total long term liabilities has changed by +$2.20M (+4.86%)